The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Mitigating Risks of Compounded Drugs Through Surveillance FDA The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and Peptide Therapy in Boise Specialized Treatment for First Responders Blueline Wellness